Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Maione

Showing results (1-10 of 131) with videos related to

Pageof 14
Sort By:
Oncogene|October 7, 2003
Treatment of non-small-cell lung cancer: state of the art and development of new biologic agentsCesare Gridelli, Antonio Rossi, Paolo Maione
Translational Lung Cancer Research|July 14, 2022
The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative reviewAlessia Spagnuolo, Paolo Maione, Cesare Gridelli
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Corticosteroids underemployment in delayed chemotherapy-induced nausea and emesis with poor adherence to American Society of Clinical Oncology guidelines: is this a reasonable clinical choice for the elderly?Cesare Gridelli, Paolo Maione, Antonio Rossi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
Single-agent chemotherapy for the treatment of elderly patients with advanced non-small-cell lung cancer: what is the best drug?Cesare Gridelli, Paolo Maione, Antonio Rossi
Reviews on Recent Clinical Trials|December 25, 2012
The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancerCesare Gridelli, Paolo Maione, Antonio Rossi
Oncology Research|April 3, 2026
Lorlatinib and Amivantamab: A Paradigm Shift in <i>EGFR</i> and <i>ALK</i> Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision MakingPaolo Maione, Valentina Palma, Cesare Gridelli
Critical Reviews in Oncology/Hematology|April 22, 2008
The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancerCesare Gridelli, Antonio Rossi, Paolo Maione
Current Opinion in Oncology|February 24, 2005
Treatment of non-small cell lung cancer and targeted therapies: where are we?Cesare Gridelli, Antonio Rossi, Paolo Maione
Expert Opinion on Emerging Drugs|September 26, 2018
Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitorsAlessia Spagnuolo, Paolo Maione, Cesare Gridelli
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment--first-line therapyCesare Gridelli, Antonio Rossi, Paolo Maione
Pageof 14

Showing results (1-10 of 131) with videos related to

Sort By:
Pageof 14
Oncogene|October 7, 2003
Treatment of non-small-cell lung cancer: state of the art and development of new biologic agentsCesare Gridelli, Antonio Rossi, Paolo Maione
Translational Lung Cancer Research|July 14, 2022
The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative reviewAlessia Spagnuolo, Paolo Maione, Cesare Gridelli
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Corticosteroids underemployment in delayed chemotherapy-induced nausea and emesis with poor adherence to American Society of Clinical Oncology guidelines: is this a reasonable clinical choice for the elderly?Cesare Gridelli, Paolo Maione, Antonio Rossi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
Single-agent chemotherapy for the treatment of elderly patients with advanced non-small-cell lung cancer: what is the best drug?Cesare Gridelli, Paolo Maione, Antonio Rossi
Reviews on Recent Clinical Trials|December 25, 2012
The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancerCesare Gridelli, Paolo Maione, Antonio Rossi
Oncology Research|April 3, 2026
Lorlatinib and Amivantamab: A Paradigm Shift in <i>EGFR</i> and <i>ALK</i> Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision MakingPaolo Maione, Valentina Palma, Cesare Gridelli
Critical Reviews in Oncology/Hematology|April 22, 2008
The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancerCesare Gridelli, Antonio Rossi, Paolo Maione
Current Opinion in Oncology|February 24, 2005
Treatment of non-small cell lung cancer and targeted therapies: where are we?Cesare Gridelli, Antonio Rossi, Paolo Maione
Expert Opinion on Emerging Drugs|September 26, 2018
Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitorsAlessia Spagnuolo, Paolo Maione, Cesare Gridelli
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment--first-line therapyCesare Gridelli, Antonio Rossi, Paolo Maione
Pageof 14